Finding the triggers of inflammation

By Rob Clancy, staff writer

Chronic or acute inflammation can contribute to a range of ailments – some potentially deadly – including stroke, respiratory and heart disease, cancer, arthritis, asthma, dementia, multiple sclerosis, and diabetes. In May, a study by Associate Professor Kate Lawlor and collaborator Professor Vince James (WEHI) published in Nature Communications shed light on the potential triggers of inflammation. 

Dr Kate Lawlor's research at Hudson Institute aims at taming inflammation.
Associate Professor Kate Lawlor

The research focused on the cytokine, interleukin-1ß (IL-1ß), which is critical to clearing infections but is also associated with sepsis and driving autoinflammatory and inflammatory diseases including rheumatoid arthritis, Type 2 diabetes, and atherosclerosis.

Previous IL-1ß research had focused on understanding how it is triggered and how inhibiting this process or neutralising IL-1ß could reduce inflammation. However, little was known about how the precursor IL-1ß protein is regulated.

Inflammatory disease treatments

The team discovered a key event that contributes to the depletion of inactive IL-1ß and limits access to the enzyme that activates IL-1ß. The potential trigger of inflammation discovery is a major step in understanding how IL-1ß levels could be manipulated to limit inflammatory responses and developing treatments for diseases associated with excessive inflammation.

Collaborators | Monash University; University of Melbourne; WEHI

Funders | National Health and Medical Research Council (NHMRC)

Contact us

Hudson Institute communications
t: + 61 3 8572 2
761
e: communications@hudson.org.au

About Hudson Institute

Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More

Hudson News

Get the inside view on discoveries and patient stories

“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”

Alana Chantry